Update on hormones, menopause, and heart disease: Evaluating professional responses to the women's health initiative

Health Care for Women International

Volumn 29, Issue 7, 2008, Pages 720-737

  Derry, Paula S ^a,b  

^a Paula Derry Enterprises in Health Psychology   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNITED STATES;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; UNITED STATES;

EID: 48849097608     PISSN: 07399332     EISSN: 10964665     Source Type: Journal    
DOI: 10.1080/07399330802179122     Document Type: Conference Paper

References (52)

1. American Association of Clinical Endocrinologists (AACE) Menopause Guidelines Revision Task Force. (2006). Medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocrinology Practice, 12, 315-337.
2. American Association of Clinical Endocrinologists (AACE). (2008). Position statement on hormone replacement therapy (HRT) and cardiovascular risk. Retrieved January 8, 2008, from http://www.aace.com/pub/guidelines/ HRTRiskposition statement.pdf
3. Barrett-Connor, E., & Grady, D. (1998). Hormone replacement therapy, heart disease, and other considerations. Annual Review of Public Health, 19, 55-72.
4. Barrett-Connor, E., & Stuenkel, C. (1999). Hormones and heart disease in women. Journal of Clinical Endocrinology and Metabolism, 84, 1848-1853.
5. Brody, J. (1997, August 28). Personal Health column, N.Y. Times Health Section.
6. Burgermeister, J. (2003). Head of German medicines body likens HRT to thalidomide. British Medical Journal, 327, 767.
7. Chlebowski, R., Hendrix, S., Langer, R., Stefanick, M., Gass, M., Lane, D., et al. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. Journal of the American Medical Association, 289, 3243-3253.
8. Clarkson, T. (1998, November). Estrogens, phytoestrogens, SERMS, and postmenopausal coronary artery atherosclerosis. Paper presented at the Women's Health Research Symposium, University of Maryland, Baltimore, MD.
9. Clarkson, T. (2007). Estrogen effects on arteries vary with stage of reproductive life and exent of subclinical atherosclerosis progression. Menopause, 14, 373-384.
10. Col, N., Eckman, M., Karas, R., Pauker, S., Goldberg, R., Ross, E., et al. (1997). Patient-specific decisions about hormone replacement therapy in postmenopausal women. Journal of the American Medical Association, 277, 1140-1147.
11. Coney, S. (1994). The menopause industry. Alameda, CA: Hunter House.
12. Derry, P. (2003). Why do professionals disagree? The case of hormone replacement therapy and coronary heart disease prevention. Women and Health, 38, 3-18.
13. Derry, P. (2004). Hormones, menopause and heart disease: Making sense of the Women's Health Initiative. Women's Health Issues, 14, 212-219.
14. Federal Register. (2002). Food and Drug Administration draft guidance for clinical evaluation of combination estrogen/progestin-containing drug products (Vol. 68, January 31, 2002). Retrieved July 3, 2008 from http://www.gpoaccess.gov
15. Food and Drug Administration (FDA). (2003). Menopause and hormones. Retrieved September 10, 2003. from http://www.fda.gov/womens/ menopause/mht-FS.html
16. Glass, A., Lacey, J., Carreon, J., & Hoover, R. (2007). Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Journal of the National Cancer Institute, 99, 1152-1161.
17. Grady, D., & Barrett-Connor, E. (2007). Postmenopausal hormone therapy. British Medical Journal, 334, 860-861.
18. Grodstein, F., Manson, J., & Stampfer, M. (2006). Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. Journal of Women's Health, 15, 35-44.
19. Grodstein, F., Manson, J., & Stampfer, M. (2001). Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Annals of Internal Medicine, 135, 1-8.
20. Harman, S., Brinton, M., Cedars, M., Lobo, R., Manson, J., Merriam, V., et al. (2005). KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 8, 3-12.
21. Harman, S., Brinton, E., Clarkson, T., Heward, C., Hecht, H., et al. (2004). Is the WHI relevant to HRT started at the perimenopause? Endocrine, 24, 295-202.
22. Herrington, D. (1997). Sex, hormones, and normal cardiovascular physiology in women. In D. Julian & N. Wenger (Eds.), Women and heart disease (pp. 243-264). London: Martin Dunitz.
23. Hersh, A., Stefanick, M., & Stafford, R. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. Journal of the American Medical Association, 291, 47-53.
24. Hsia, J., Langer, R., Manson, J., Kuller, L., Johnson, K., Hendrix, S., et al. (2006). Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine, 166, 357-365.
25. Hu, F., Stampfer, M., Manson, J., Grodstein, F., Colditz, G., Speizer, F., et al. (2000). Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. New England Journal of Medicine, 343, 530-537.
26. Kolata, G., & Petersen, M. (2002, July 10). Hormone replacement study a shock to the medical system. New York Times, Health Section. Retrieved July 14, 2002, from http://www.nytimes.com/2002/07/10/health/10HORM.html
27. Manson, J., Allison, M., Rossouw, J., Carr, J., Langer, R., Hsia, J., et al. (2007). Estrogen therapy and coronary-artery calcification. New England Journal of Medicine, 356, 2591-2602.
28. Manson, J., Hsia, J., Johnson, K., Rossouw, J., Assaf, A., Lasser, N., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349, 523-534.
29. Mikkola, T., & Clarkson, T. (2006). Coronary heart disease and postmenopausal hormone therapy: Conundrum explained by timing? Journal of Womens Health, 15, 51-53.
30. Mosca, L. (2001). In reply [to Watts]. Archives of Internal Medicine, 161, 774.
31. Mosca, L., Banka, C., Benjamin, E., Berra, K., Bushnell, C., Dolor, R., et al. (2007). Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation, 115, 1481-1501.
32. National Committee for Quality Assurance. (2001). HEDIS 2001: Specifications for survey measures (vol. 3). Washington, DC: National Committee for Quality Assurance.
33. National Heart, Lung, and Blood Institute. (2002, March). Women's health and menopause: A comprehensive approach. Bethesda, MD: Author.
34. National Institutes of Health (NIH). (2002, October 23-24). Scientific workshop on menopausal hormone therapy. Bethesda, MD.
35. North American Menopause Society (NAMS). (2004). Recommendations for estrogen and progestogen use in perimenopausal and postmenopausal women: October 2004 position statement. Menopause, 11, 589-600.
36. North American Menopause Society (NAMS). (2007). Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause, 14, 168-182.
37. Notelovitz, M. (2002). Why individualizing hormone therapy is crucial. Medscape Women's Health eJournal, 7. Retrieved July 14, 2002, from http://www.medscape.com/viewarticle/438356
38. Ouyang, P., Michos, E., & Karas, R. (2006). Hoarmone replacement therapy and the cardiovascular system. Journal of the American College of Cardiology, 47, 1741-1753.
39. Phillips, L., & Langer, R. (2005). Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. Fertility and Sterility, 83, 556-558.
40. Ravdin, P., Cronin, K., Howlader, N., Berg, C., Chlebowski, R., Feuer, E., et al. (2007). The decrease in breast-cancer incidence in 2003 in the United States. New England Journal of Medicine, 356, 1670-1674.
41. Roberts, H. (2007). Hormone replacement therapy comes full circle. British Medical Journal, 335, 219-220.
42. Rossouw, J., Prentice, R., Manson, J., Wu, L., Barad, D., Baarnabei, V., et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Journal of the American Medical Association, 297, 1465-1477.
43. Salpeter, S., Walsh, J., Greyber, E., & Salpeter, E. (2006). Coronary heart disease events associated with hormone therapy in younger and older women. Journal of General Internal Medicine, 21, 363-366.
44. Shojania, K., Mariani, S., & Lundberg, G. (2002). MedGenMed's selection of the top 10 medical/health stores of 2002. Retrieved December 24, 2002, from http://www.medscape.com/viewarticle/446310
45. Snyder, U. (2002). September 2002: Harvesting controversies for women and society. Retrieved September 16, 2002, from http://www.medscape.com/ viewarticle/441028
46. Sturdee, D., & MacLennan, A. (2006). The pendulum swings back: Estrogen is now beneficial if started at the right time. Climacteric, 9, 73-74.
47. Utian, W. (2003). Foreward. In N. Santoro & S. Goldstein (Eds.), Textbook of perimenopausal gynecology (p. xi). New York: Parthenon.
48. Vickers, M., MacLennan, A., Lawton, B., Ford, D., Martin, J., Meredith, S., et al. (2007). Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): A randomised controlled trial of hormone replacement therapy in postmenopausal women. British Medical Journal, 335, 239-250.
49. Voda, A. (1997). Menopause, me and you. Binghamton, NY: Haworth Press.
50. Weiner, M., Barnhart, K., Xie, D., & Tannen, R. (2007). Hormone therapy and heart disease in young women. Menopause, 15, 1-8.
51. Women's Health Initiative (WHI) Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701-1712.
52. Writing Group for the Women's Health Initiative (WHI) Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321-333.